Results of a phase 3 randomized trial of Zanubrutinib vs. Ibrutinib

 ABSTRACT   06/2020

For more information about this resource, please submit a medical information request.

Aspen: Results of a phase 3 randomized trial of Zanubrutinib vs. Ibrutinib for patients with Waldenström macroglobulinemia

Rating

Rate this resource

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service